#ESMO26 | VOLGA | Presidential Symposium-1

In cisplatin-ineligible/refusing MIBC, neoadjuvant EV + perioperative durvalumab significantly improved EFS and OS vs the control arm.

EFS: HR 0.55 (24-month: 78% vs 69%)
OS: HR 0.58 (24-month: 83% vs 75%)
pCR: 45% vs 10%

Impressive results!

Unlike KEYNOTE-905/EV-303, EV was administered only in the neoadjuvant setting, with no adjuvant EV.

I’m looking forward to the discussion during the session.